Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 11
Submit an article Journal homepage
794
Views
61
CrossRef citations to date
0
Altmetric
Reviews

Targeting of HDAC8 and investigational inhibitors in neuroblastoma

Ina Oehme German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany +49 6221 423388; +49 6221 423277; [email protected]
,
Hedwig E Deubzer German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany +49 6221 423388; +49 6221 423277; [email protected]; University of Heidelberg, Department of Pediatric Oncology, Hematology and Immunology, INF 430, D-69120 Heidelberg, Germany
,
Marco Lodrini German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany +49 6221 423388; +49 6221 423277; [email protected]; University of Heidelberg, Department of Pediatric Oncology, Hematology and Immunology, INF 430, D-69120 Heidelberg, Germany
,
Till Milde German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany +49 6221 423388; +49 6221 423277; [email protected]
&
Olaf Witt German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany +49 6221 423388; +49 6221 423277; [email protected]
Pages 1605-1617 | Published online: 28 Sep 2009

Bibliography

  • Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3(3):203-16
  • Westermann F, Schwab M. Genetic parameters of neuroblastomas. Cancer Lett 2002;184(2):127-47
  • Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5(1):37-50
  • Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6(1):38-51
  • Buchwald M, Kramer OH, Heinzel T. HDACi–targets beyond chromatin. Cancer Lett 2009;280(2):160-7
  • Tang Y, Zhao W, Chen Y, Acetylation is indispensable for p53 activation. Cell 2008;133(4):612-26
  • Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009;107(4):600-8
  • Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009;15(12):3947-57
  • Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978;14(1):105-13
  • Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265(28):17174-9
  • Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996;272(5260):408-11
  • Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009;277(1):8-21
  • Finnin MS, Donigian JR, Cohen A, Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401(6749):188-93
  • Nielsen TK, Hildmann C, Dickmanns A, Crystal structure of a bacterial class 2 histone deacetylase homologue. J Mol Biol 2005;354(1):107-20
  • Sternson SM, Wong JC, Grozinger CM, Schreiber SL. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett 2001;3(26):4239-42
  • Oehme I, Deubzer HE, Wegener D, Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009;15(1):91-9
  • Deubzer HE, Ehemann V, Westermann F, Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer 2008;122(8):1891-900
  • Ouwehand K, de Ruijter AJ, van Bree C, Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins. FEBS Lett 2005;579(6):1523-8
  • Wegener D, Deubzer HE, Oehme I, HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. Anticancer Drugs 2008;19(9):849-57
  • Jaboin J, Wild J, Hamidi H, MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62(21):6108-15
  • Rocchi P, Tonelli R, Camerin C, p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 2005;13(6):1139-44
  • Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-84
  • De los Santos M, Zambrano A, Aranda A. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther 2007;6(4):1425-32
  • Subramanian C, Opipari AWJr, Bian X, Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102(13):4842-7
  • Subramanian C, Jarzembowski JA, Opipari AWJr, CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A. Neoplasia 2007;9(6):495-503
  • Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004;101(52):18030-5
  • Muhlethaler-Mottet A, Meier R, Flahaut M, Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 2008;7:55
  • Deubzer HE, Ehemann V, Kulozik AE, Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro. Cancer Lett 2008;264(1):21-8
  • Khan N, Jeffers M, Kumar S, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409(2):581-9
  • Cinatl J Jr, Cinatl J, Scholz M, Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 1996;7(7):766-73
  • Cinatl J Jr, Cinatl J, Driever PH, Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 1997;8(10):958-63
  • Cinatl J Jr, Kotchetkov R, Blaheta R, Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol 2002;20(1):97-106
  • Condorelli F, Gnemmi I, Vallario A, Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008;153(4):657-68
  • Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63(13):3637-45
  • Lagger G, O'Carroll D, Rembold M, Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21(11):2672-81
  • Gui CY, Ngo L, Xu WS, Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004;101(5):1241-6
  • Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998;95(12):6791-6
  • Furchert SE, Lanvers-Kaminsky C, Juurgens H, Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007;120(8):1787-94
  • Witt O, Deubzer HE, Lodrini M, Targeting histone deacetylases in neuroblastoma. Curr Pharm Des 2009;15(4):436-47
  • Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009;280(2):192-200
  • Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002;11(12):1695-713
  • Kelly WK, O'Connor OA, Krug LM, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923-31
  • Mann BS, Johnson JR, Cohen MH, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12(10):1247-52
  • Gore L, Rothenberg ML, O'Bryant CL, A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14(14):4517-25
  • Gojo I, Jiemjit A, Trepel JB, Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109(7):2781-90
  • Ryan QC, Headlee D, Acharya M, Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23(17):3912-22
  • Klimek VM, Fircanis S, Maslak P, Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008;14(3):826-32
  • Schrump DS, Fischette MR, Nguyen DM, Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 2008;14(1):188-98
  • Schilling FH, Spix C, Berthold F, Neuroblastoma screening at one year of age. N Engl J Med 2002;346(14):1047-53
  • Fouladi M, Park J, Sun J, A phase I trial of vorinostat in children with refractory solid tumors: a Children's Oncology Group Study. Abstract ASCO07L_34327 2007
  • Garcia-Manero G, Yang H, Bueso-Ramos C, Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111(3):1060-6
  • Siu LL, Pili R, Duran I, Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26(12):1940-7
  • Piekarz RL, Frye AR, Wright JJ, Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12(12):3762-73
  • Fouladi M, Furman WL, Chin T, Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol 2006;24(22):3678-85
  • Steele NL, Plumb JA, Vidal L, A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14(3):804-10
  • Stimson L, La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009;280(2):177-83
  • Shimada H, Umehara S, Monobe Y, International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92(9):2451-61
  • de Ruijter AJ, van Gennip AH, Caron HN, Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370(Pt 3):737-49
  • Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338(1):17-31
  • Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem 2004;93(1):57-67
  • Yang WM, Yao YL, Sun JM, Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem 1997;272(44):28001-7
  • Dangond F, Hafler DA, Tong JK, Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochem Biophys Res Commun 1998;242(3):648-52
  • Emiliani S, Fischle W, Van Lint C, Characterization of a human RPD3 ortholog, HDAC3. Proc Natl Acad Sci USA 1998;95(6):2795-800
  • Zhang X, Ozawa Y, Lee H, Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev 2005;19(7):827-39
  • Hu E, Chen Z, Fredrickson T, Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 2000;275(20):15254-64
  • Van den Wyngaert I, de Vries W, Kremer A, Cloning and characterization of human histone deacetylase 8. FEBS Lett 2000;478(1-2):77-83
  • Buggy JJ, Sideris ML, Mak P, Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J 2000;350(Pt 1):199-205
  • Lee H, Rezai-Zadeh N, Seto E. Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol 2004;24(2):765-73
  • Vannini A, Volpari C, Filocamo G, Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004;101(42):15064-9
  • Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9(3):206-18
  • Choi JH, Kwon HJ, Yoon BI, Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92(12):1300-4
  • Wilson AJ, Byun DS, Popova N, Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281(19):13548-58
  • Kim JH, Choi YK, Kwon HJ, Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 2004;19(2):218-24
  • Toh Y, Yamamoto M, Endo K, Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep 2003;10(2):333-8
  • Giannini R, Cavallini A. Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma. Anticancer Res 2005;25(6B):4287-92
  • Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 2001;287(3):705-13
  • Waltregny D, North B, Van Mellaert F, Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem 2004;48(3):273-90
  • Halkidou K, Gaughan L, Cook S, Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59(2):177-89
  • Krusche CA, Wulfing P, Kersting C, Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005;90(1):15-23
  • Sasaki H, Moriyama S, Nakashima Y, Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004;46(2):171-8
  • Bartling B, Hofmann HS, Boettger T, Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer 2005;49(2):145-54
  • Zhu P, Martin E, Mengwasser J, Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5(5):455-63
  • Huang BH, Laban M, Leung CH, Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12(4):395-404
  • Song J, Noh JH, Lee JH, Increased expression of histone deacetylase 2 is found in human gastric cancer. Apmis 2005;113(4):264-8
  • Haberland M, Mokalled MH, Montgomery RL, Olson EN. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 2009;23(14):1625-30
  • Montgomery RL, Davis CA, Potthoff MJ, Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21(14):1790-802
  • Knutson SK, Chyla BJ, Amann JM, Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J 2008;27(7):1017-28
  • Bhaskara S, Chyla BJ, Amann JM, Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008;30(1):61-72
  • Montgomery RL, Potthoff MJ, Haberland M, Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008;118(11):3588-97
  • De Preter K, Vandesompele J, Heimann P, Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 2006;7(9):R84
  • Nakagawa M, Oda Y, Eguchi T, Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007;18(4):769-74
  • Lee H, Sengupta N, Villagra A, Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. Mol Cell Biol 2006;26(14):5259-69
  • Balasubramanian S, Ramos J, Luo W, A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008;22(5):1026-34
  • Durst KL, Lutterbach B, Kummalue T, The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol 2003;23(2):607-19
  • Takami Y, Nakayama T. N-terminal region, C-terminal region, nuclear export signal, and deacetylation activity of histone deacetylase-3 are essential for the viability of the DT40 chicken B cell line. J Biol Chem 2000;275(21):16191-201
  • Longworth MS, Laimins LA. Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene 2006;25(32):4495-500
  • Waltregny D, De Leval L, Glenisson W, Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol 2004;165(2):553-64
  • Dowling DP, Gantt SL, Gattis SG, Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Biochemistry 2008;47(51):13554-63
  • Riester D, Wegener D, Hildmann C, Schwienhorst A. Members of the histone deacetylase superfamily differ in substrate specificity towards small synthetic substrates. Biochem Biophys Res Commun 2004;324(3):1116-23
  • Hu E, Dul E, Sung CM, Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003;307(2):720-8
  • Krennhrubec K, Marshall BL, Hedglin M, Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007;17(10):2874-8
  • Haggarty SJ, Koeller KM, Wong JC, Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003;100(8):4389-94
  • Parmigiani RB, Xu WS, Venta-Perez G, HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci USA 2008;105(28):9633-8
  • Sandor V, Bakke S, Robey RW, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8(3):718-28

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.